glp 1 for metabolic syndrome Resmetirom and GLP-1 agonists MASH: complementary rather than exclusive GLP-1 for Prevention: Using Drugs

The compound was originally developed in the 1980s at the University of Arizona

Development of pharmacological and biological therapies for intracerebral hemorrhage Early pharmacological attempts (1960s1980s) The earliest explorations into drug therapy for spontaneous ICH, particularly hypertensive basal ganglia hemorrhage, were largely empirical

not clinical, diagnostic, therapeutic, veterinary, or human-use guidance

It positions the combination as weight or glucose management layered onto existing psychiatric care

We found consistent effects of ALC significantly reducing serum ammonia level and improving NCT in patients with West Haven grade 0, 1, 2 and 3 encephalopathy versus placebo prompting that ALC may be comparable to the current medications of HE, such as non-absorbable disaccharides, rifaximin, branched chain amino acids (BCAA) and L-ornithine-L-aspartate (LOLA).29 Furthermore, ALC appears to be more well-tolerated and safe with relatively low cost

Sanjana Jain, BS